Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in North Carolina

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Exposure Risk

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy heritage emphasized broad awareness of wellness principles and the importance of informed decision-making in healthcare. Within this context, discussions around metabolic health and diabetes management have become increasingly prominent, reflecting evolving scientific understanding of chronic disease. As public health narratives have matured, a natural pivot has emerged toward examining specific therapeutic exposures and their potential downstream consequences. The widespread use of medications such as Ozempic, originally developed for glycemic control, has introduced new dimensions to patient safety considerations. This transition from general health education to targeted exposure awareness is particularly relevant when considering gastrointestinal complications that may arise from prolonged use.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Its mechanism of action includes slowing gastric emptying, which is a therapeutic effect that can become pathological in some patients. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy showing retained food after a standardized meal. The overlap between Ozempic's intended pharmacodynamic effect and the clinical syndrome of gastroparesis raises important questions about causation, adequate warnings, and legal recourse for affected patients. Clinical evidence from placebo-controlled trials demonstrates that gastrointestinal adverse reactions are significantly more common with Ozempic than placebo. In pooled trials, gastrointestinal adverse reactions occurred in 32.7% of patients receiving Ozempic 0.5 mg and 36.4% of those receiving 1 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to these reactions was also higher: 3.1% for 0.5 mg and 3.8% for 1 mg versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (3.5% at 0.5 mg, 2.7% at 1 mg), gastroesophageal reflux disease (1.9% at 0.5 mg, 1.5% at 1 mg), and gastritis (0.8% at 0.5 mg, 0.4% at 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate that Ozempic can induce symptoms consistent with gastroparesis, though the label does not explicitly list gastroparesis as an adverse reaction.

Mechanistic Evidence and Postmarketing Reports

Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This effect is dose-dependent and can persist beyond the acute treatment period. Postmarketing reports have documented pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, attributed to retained gastric contents despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This finding underscores the potential for clinically significant delayed gastric emptying, which is the hallmark of gastroparesis. The label acknowledges that available data are insufficient to recommend specific preoperative fasting modifications or temporary discontinuation strategies to mitigate this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This gap in guidance may be relevant to patients who develop gastroparesis symptoms while on Ozempic. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a central concern. The label does not explicitly warn about gastroparesis as a potential adverse effect, despite the known mechanism of delayed gastric emptying and the clinical trial data showing elevated rates of nausea, vomiting, dyspepsia, and gastroesophageal reflux disease. Patients who develop persistent symptoms of gastroparesis may not be adequately informed about the possible link to their medication.

Legal Considerations and Statute of Limitations in North Carolina

For attorneys representing affected patients, key considerations include establishing a temporal relationship between Ozempic initiation and symptom onset, documenting objective evidence of delayed gastric emptying (e.g., gastric emptying scintigraphy), and ruling out other causes such as diabetes-related autonomic neuropathy or idiopathic gastroparesis. The timeline between exposure and documented harm is critical: symptoms often emerge during dose escalation, as noted in the label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but may persist or worsen with continued use. In North Carolina, the statute of limitations for product liability claims, including failure to warn, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, the clock may start when a patient is diagnosed with gastroparesis or when symptoms become severe enough to prompt medical evaluation. Given that gastroparesis can develop insidiously, patients should seek legal counsel promptly to preserve their rights. Attorneys should gather medical records documenting Ozempic prescription, dose changes, symptom progression, diagnostic tests, and any communications with healthcare providers about gastrointestinal side effects. The postmarketing aspiration reports (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98) may also be used to argue that the manufacturer had notice of the risk of clinically significant delayed gastric emptying but did not update the label accordingly. In summary, the evidence supports a plausible link between Ozempic and gastroparesis through the drug's mechanism of delayed gastric emptying and clinical trial data showing elevated rates of gastrointestinal adverse reactions. The label's warnings are limited, and postmarketing reports of aspiration highlight the potential severity of this effect. Patients in North Carolina who develop gastroparesis after starting Ozempic should be aware of the statute of limitations and consult an attorney to evaluate their case.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for product liability claims, including failure to warn, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, the clock may start when a patient is diagnosed with gastroparesis or when symptoms become severe enough to prompt medical evaluation. It is crucial to consult an attorney promptly to preserve your rights.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is known to slow gastric emptying as part of its mechanism of action. Clinical trials show significantly higher rates of gastrointestinal adverse reactions such as nausea, vomiting, dyspepsia, and gastroesophageal reflux disease compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the label does not explicitly list gastroparesis, the drug can induce symptoms consistent with gastroparesis, and postmarketing reports of aspiration highlight the potential for clinically significant delayed gastric emptying (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

What evidence do I need for an Ozempic gastroparesis lawsuit?

Key evidence includes medical records documenting Ozempic prescription and dose changes, symptom progression, diagnostic tests such as gastric emptying scintigraphy confirming delayed gastric emptying, and any communications with healthcare providers about gastrointestinal side effects. Establishing a temporal relationship between Ozempic initiation and symptom onset is critical.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.